Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07811141
Starting soon Observational

Observational Study of IgE-Mediated Leguminous Allergies in a Pediatric Population

NCT07811141 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Observational
Started
2026-09
Last updated
2026-10-01

Condition(s) studied

Hypersensitivity, FoodLegumes Allergy

Study summary

Prospective, monocentric, observational study with standard care follow-up during 5 years or until the patient reaches the age of 18.

The aim of this study is to prospectively and comprehensively assess the characteristics of patients aged 6 months to 17 years with leguminous allergy (excluding peanut) and their reactions to leguminous, including both medical history and prospective follow-up for 5 years from inclusion, or until the age of 18. The study aims to improve the understanding of these allergies, provide epidemiological data, and optimize diagnostic and clinical management. A biobank will also be established, with plasma (one whole blood sample collected at the inclusion) in order to validate future diagnostic tests.

Eligibility

Sex
ALL
Min age
6 Months
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * Subjects aged 6 months to 17 years old * Medical diagnosis of allergy to one or more leguminous : * Clinical reaction following real-life exposure AND positive skin and/or biological sensitization * Allergy confirmed by a positive oral food challenge (OFC) in cases of sensitization without a history of clinical reaction * Subjects seen in a pediatric pneumo-allergy unit (consultation or hospitalization) Exclusion Criteria: * Isolated IgE-mediated peanut allergy * Patients aged 18 years or older * Minor patient or legal representant (parental authority) Refusal

Primary outcome measure(s)

  • Prospectively study, among the leguminous, the type of leguminous (excluding peanut) responsible for the allergy. — Baseline (Inclusion) 1 Year from the Inclusion 5 years from the inclusion, or until the age of 18
    The primary endpoint will be the number of allergy diagnoses for each type of leguminous (excluding peanut), among : * Green peas * Split peas (dried green peas) * Yellow or blond dried peas * Chickpeas * Green, red, or blond lentils * Green, Kidney, White or Mung beans * Soybean * Lupin * Fenugreek * Fava bean (broad bean) * Beluga lentils * Black-eyed peas (cowpeas), adzuki beans,and urad beans * Alfalfa

Trial sites (1)

FacilityCityRegionStatus
CHU Lille Lille France

More University Hospital, Lille trials in France

Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections. Starting soon
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Recruiting
Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures Active, not recruiting
Performance of Carbon Dioxide (CO2)-Derived Parameters in Predicting Low Cardiac Output Syndrome Recruiting
Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07811141 on ClinicalTrials.gov ↗ ← All trials in France